GO:1990409 adrenomedullin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990409 adrenomedullin binding describes the molecular function of selectively binding the peptide hormone adrenomedullin (AM).
• The best-characterized adrenomedullin-binding protein is complement factor H (CFH), also known as adrenomedullin-binding protein 1 (AMBP-1).
• Adrenomedullin binding regulates the bioavailability and biological activity of AM in cardiovascular, neuroprotective, and inflammatory contexts.
• AM and AMBP-1 co-administration reduces tissue injury and inflammation in preclinical models of shock, sepsis, and ischemia-reperfusion.
• Adrenomedullin binding sites are distributed in the brain and peripheral tissues, indicating broad physiological relevance.
• Studying GO:1990409 requires methods such as binding assays, knockout/knock-in models, and CRISPR-based functional screens.
Description
Adrenomedullin binding (GO:1990409) is a molecular function defined as the selective interaction with adrenomedullin (AM), a multifunctional peptide hormone. This binding event is central to modulating AM availability and activity in diverse physiological systems, including cardiovascular homeostasis, neuroprotection, and the septic response. The most extensively studied adrenomedullin-binding protein is complement factor H (CFH), which also functions as adrenomedullin-binding protein 1 (AMBP-1). Researchers investigate GO:1990409 to understand how AM signaling is buffered, transported, or presented to its receptors in health and disease. Because AM and its binding protein have shown protective effects in preclinical models of hemorrhagic shock, sepsis, and hepatic ischemia-reperfusion, this GO term is directly relevant to translational studies. Understanding the molecular details of adrenomedullin binding can inform therapeutic strategies that target AM pathways.
adrenomedullin binding At A Glance
| GO ID | GO:1990409 |
|---|---|
| GO term | adrenomedullin binding |
| Ontology | molecular_function |
| Synonym | AM binding |
| Major function | Binding to the peptide hormone adrenomedullin (AM) |
| Major binding protein | Complement factor H (CFH), also known as adrenomedullin-binding protein 1 (AMBP-1) |
| Physiological contexts | Cardiovascular protection, neuroprotection, septic response, pancreatic physiology |
| Research relevance | Target for shock, sepsis, ischemia-reperfusion, and inflammation studies |
What Is GO:1990409?
In the Gene Ontology, adrenomedullin binding (GO:1990409) is defined as the molecular function of binding to adrenomedullin (AM). It encompasses any protein or macromolecular complex that selectively interacts with AM through non-covalent interactions, thereby influencing AM stability, localization, or receptor engagement. This term is distinct from adrenomedullin receptor activity, which involves signal transduction upon AM binding.
Why Is adrenomedullin binding Important in Cell Biology?
Adrenomedullin binding is critical because it modulates the bioavailability and bioactivity of AM, a peptide with potent vasodilatory, anti-inflammatory, and neuroprotective effects. The interaction between AM and its binding protein AMBP-1 (CFH) has been shown to attenuate tissue injury in preclinical models of hemorrhagic shock, sepsis, and hepatic ischemia-reperfusion. Therefore, understanding GO:1990409 provides mechanistic insight into how AM signaling is regulated and offers potential therapeutic targets for critical care and inflammatory diseases.
• Regulates circulating levels and local activity of adrenomedullin, a key vasoactive peptide.
• Modulates cardiovascular responses in sepsis and hemorrhagic shock.
• Contributes to neuroprotection through AMBP-1 interactions.
• Influences pancreatic physiology via AM and its binding protein.
• Attenuates tissue injury and inflammation in hepatic ischemia-reperfusion.
• Provides a molecular target for therapeutic development in critical illness.
• Helps explain the pleiotropic effects of AM in different tissues.
• Enables research on AM bioavailability and receptor presentation.
• Links complement regulation (CFH) with peptide hormone biology.
• Supports biomarker and drug discovery efforts targeting AM pathways.
Molecular Mechanism of adrenomedullin binding
Adrenomedullin as a ligand
In simple terms: Adrenomedullin is a small protein hormone that circulates in the blood and acts on many tissues.
Adrenomedullin (AM) is a 52-amino-acid peptide hormone with broad physiological actions, including vasodilation and anti-inflammation. Its bioavailability is influenced by binding proteins that sequester or present it to receptors.
Complement factor H as AMBP-1
In simple terms: A protein called complement factor H can also bind adrenomedullin and is therefore named AMBP-1.
Complement factor H (CFH) was identified as adrenomedullin-binding protein 1 (AMBP-1) through its alternative identity. This dual function links complement regulation with AM biology, suggesting that CFH/AMBP-1 modulates AM activity in plasma and tissues.
Binding specificity and affinity
In simple terms: The binding between adrenomedullin and its protein partners is selective and can be measured in the lab.
Adrenomedullin binding sites have been mapped in rat brain and peripheral tissues, indicating specific interaction sites. The binding is saturable and reversible, typical of receptor-ligand or carrier-protein interactions.
Functional consequences of binding
In simple terms: When adrenomedullin binds to its binding protein, it can change how the hormone works in the body.
AMBP-1 binding can enhance or inhibit AM effects depending on context. In neuroprotection, AMBP-1 appears to potentiate AM's protective actions. In sepsis and shock models, co-administration of AM and AMBP-1 reduces organ injury and inflammation.
Regulation of adrenomedullin binding
In simple terms: The amount of binding protein and adrenomedullin in the body can go up or down, affecting how much binding occurs.
Levels of AM and AMBP-1 are dynamically regulated in response to stress, inflammation, and injury. For example, in sepsis, both AM and AMBP-1 levels change, influencing the extent of binding and downstream effects.
Key Genes Involved in GO:1990409 adrenomedullin binding
The following genes and proteins are directly implicated in adrenomedullin binding or its functional consequences.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CFH | Encodes complement factor H, also known as adrenomedullin-binding protein 1 (AMBP-1) | Central to GO:1990409; links complement and AM biology |
| ADM | Encodes adrenomedullin, the ligand for GO:1990409 | Provides the peptide that is bound; key for binding assays |
| CALCRL | Encodes calcitonin receptor-like receptor, a component of AM receptors | Downstream signaling after AM binding; not a binding protein per se |
| RAMP2 | Encodes receptor activity-modifying protein 2, required for AM receptor function | Modulates AM signaling; relevant to binding consequences |
| RAMP3 | Encodes receptor activity-modifying protein 3, another AM receptor component | Affects AM receptor specificity and binding outcomes |
| CFHR1 | Complement factor H-related protein 1 | May share structural homology with CFH; potential AM binding |
| CFHR3 | Complement factor H-related protein 3 | Similar to CFH; possible role in AM binding |
| C4BPA | Complement component 4 binding protein alpha | Complement regulator; not directly linked to AM binding |
| CRP | C-reactive protein | Inflammatory marker; may influence AM levels in sepsis |
| IL6 | Interleukin 6 | Pro-inflammatory cytokine; modulates AM expression in sepsis |
| TNF | Tumor necrosis factor | Inflammatory cytokine; affects AM and AMBP-1 in shock |
| NOS3 | Endothelial nitric oxide synthase | Mediates vasodilation downstream of AM |
| VEGFA | Vascular endothelial growth factor A | Angiogenic factor; AM may interact in vascular biology |
| MAPK1 | Mitogen-activated protein kinase 1 | Signaling downstream of AM receptor activation |
| AKT1 | AKT serine/threonine kinase 1 | Survival signaling; may be modulated by AM |
| NFKB1 | Nuclear factor kappa B subunit 1 | Inflammatory transcription factor; AM can inhibit NF-kB |
| HIF1A | Hypoxia inducible factor 1 subunit alpha | Hypoxia response; AM is induced by hypoxia |
| STAT3 | Signal transducer and activator of transcription 3 | Transcription factor; may mediate AM effects |
How Is adrenomedullin binding Regulated?
Adrenomedullin binding is regulated by the availability of both AM and its binding proteins, which are dynamically expressed in response to physiological stress, inflammation, and injury. In sepsis and hemorrhagic shock, circulating levels of AM and AMBP-1 change, altering the balance of bound versus free AM. Additionally, complement activation and inflammatory cytokines such as TNF and IL-6 can modulate CFH/AMBP-1 expression, indirectly affecting AM binding. Hypoxia and HIF-1α signaling induce AM expression, potentially increasing binding interactions.
adrenomedullin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CFH | Sepsis, ischemia-reperfusion injury | CFH knockout mouse; AM/AMBP-1 co-treatment in rabbit models |
| ADM | Septic shock, cardiovascular dysfunction | Adm knockout or transgenic mice; LPS-induced sepsis models |
| CALCRL | Vascular tone regulation | Conditional knockout in endothelial cells |
| RAMP2 | Cardiovascular development and function | Ramp2 knockout mice |
| NFKB1 | Inflammation in sepsis | NF-kB reporter mice; AM treatment in sepsis models |
Sepsis and septic shock
Adrenomedullin and its binding protein AMBP-1 play a critical role in the septic response. Preclinical studies show that co-administration of AM and AMBP-1 improves cardiovascular function and reduces mortality in sepsis models. The binding of AM to AMBP-1 may modulate the excessive vasodilation and inflammation characteristic of septic shock.
Ischemia-reperfusion injury
In hepatic ischemia-reperfusion injury, human adrenomedullin and its binding protein attenuate tissue injury and inflammation in rabbits. This suggests that enhancing AM binding or AM/AMBP-1 co-treatment could be protective in ischemic conditions.
Neuroprotection
AMBP-1 has been implicated in neuroprotection, where it may enhance the protective effects of AM in the brain. The presence of adrenomedullin binding sites in the brain supports a role in central nervous system physiology.
Pancreatic physiology
Adrenomedullin and its binding protein regulate pancreatic physiology, including insulin secretion and exocrine function. Dysregulation of AM binding may contribute to pancreatic disorders, though further research is needed.
From adrenomedullin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CFH/AMBP-1 directly bind AM in vivo? | Knock-in of tagged CFH (e.g., HA-tag) in mice |
| What is the effect of AM binding on sepsis outcomes? | CFH knockout mice subjected to LPS-induced sepsis |
| Can a point mutation in CFH abolish AM binding? | CRISPR-mediated point mutation in CFH binding domain |
| Does overexpression of AMBP-1 protect against ischemia-reperfusion? | Transgenic overexpression of CFH in rabbits or mice |
| Which tissues express AM binding sites? | Reporter mice with fluorescently tagged AM or AMBP-1 |
| Is AM binding required for neuroprotection? | Neuron-specific CFH knockout mice |
How to Study the adrenomedullin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Specific binding sites for AM | Mapping AM binding in tissues |
| Surface plasmon resonance | Binding affinity and kinetics | Characterizing AM-AMBP-1 interaction |
| Co-immunoprecipitation | Protein-protein interactions | Identifying novel AM-binding proteins |
| RNA-seq | Gene expression levels | Measuring Adm and Cfh expression in disease |
| CRISPR knockout | Loss-of-function phenotypes | Testing role of CFH in AM binding |
| Transgenic overexpression | Gain-of-function effects | Evaluating protective role of AMBP-1 |
| Immunohistochemistry | Tissue localization of AM and AMBP-1 | Mapping binding sites in brain and periphery |
| ELISA | Circulating AM and AMBP-1 levels | Biomarker studies in sepsis |
Binding assays
Radioligand binding assays using iodinated adrenomedullin can quantify specific binding sites in tissues or cells. Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) can measure affinity and kinetics of AM-AMBP-1 interactions.
Genetic models
Knockout and transgenic models for Adm, Cfh, Calcrl, and Ramp2 have been used to study AM biology in vivo. These models help dissect the contribution of AM binding to physiological and pathological outcomes.
Expression profiling
RNA-seq and quantitative PCR can measure expression levels of AM, AMBP-1, and related genes in disease models. This helps correlate binding protein levels with disease severity.
Proteomic and interactomic approaches
Co-immunoprecipitation followed by mass spectrometry can identify novel AM-binding proteins. Proximity ligation assays can visualize AM-AMBP-1 interactions in situ.
How CRISPR Can Be Used to Study GO:1990409 adrenomedullin binding
Knockout
CRISPR-Cas9 knockout of CFH or ADM can abolish adrenomedullin binding, allowing researchers to study loss-of-function phenotypes in sepsis, ischemia, and neuroprotection models. Knockout of CFH may also affect complement regulation, so careful controls are needed.
Point Mutation
Introducing point mutations in the AM-binding domain of CFH can dissect which residues are critical for binding without completely eliminating protein function. This approach helps separate AM binding from complement regulatory functions.
Knock-in
Knock-in of tagged CFH (e.g., HA or GFP) enables visualization and pull-down of the AM-binding protein in vivo. This can reveal tissue-specific expression and interaction partners.
Overexpression
Overexpression of CFH/AMBP-1 or AM via CRISPR activation or transgenic constructs can test whether increased binding protects against inflammatory injury, as seen in hepatic ischemia-reperfusion models.
How EDITGENE Supports adrenomedullin binding Research
Researchers studying adrenomedullin binding-related genes often need to determine whether a candidate gene is causally involved in AM binding and its downstream effects. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for adrenomedullin binding research.
Frequently Asked Questions About adrenomedullin binding
What is adrenomedullin binding?
Adrenomedullin binding (GO:1990409) is the molecular function of selectively binding the peptide hormone adrenomedullin (AM), often mediated by proteins such as complement factor H (AMBP-1).
What genes are involved in adrenomedullin binding?
Key genes include CFH (AMBP-1), ADM (adrenomedullin), and receptor components CALCRL and RAMP2/3.
What is the role of AMBP-1 in adrenomedullin binding?
AMBP-1, also known as complement factor H, binds adrenomedullin and modulates its bioavailability and activity in cardiovascular and inflammatory contexts.
How is adrenomedullin binding studied?
Common methods include radioligand binding assays, surface plasmon resonance, co-immunoprecipitation, and CRISPR knockout models.
What diseases are associated with adrenomedullin binding?
Sepsis, hemorrhagic shock, ischemia-reperfusion injury, and neuroprotection are linked to AM and its binding protein.
Can CRISPR be used to study adrenomedullin binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can dissect the function of AM-binding proteins.
What is the GO ID for adrenomedullin binding?
The Gene Ontology ID is GO:1990409.
Is adrenomedullin binding the same as adrenomedullin receptor activity?
No, adrenomedullin binding refers to the binding event itself, while receptor activity involves signal transduction upon binding.
What are the synonyms for adrenomedullin binding?
The official synonym is AM binding.
Which tissues express adrenomedullin binding sites?
Adrenomedullin binding sites have been found in rat brain and peripheral tissues, including cardiovascular and pancreatic tissues.
Conclusion
Adrenomedullin binding (GO:1990409) is a molecular function critical for regulating the pleiotropic hormone adrenomedullin. The interaction between AM and its binding protein AMBP-1 (CFH) modulates cardiovascular, neuroprotective, and inflammatory responses, with therapeutic potential in sepsis, shock, and ischemia-reperfusion injury. Continued research using CRISPR models and binding assays will further elucidate the mechanisms and disease relevance of this important interaction.
References
- 1. Sim RB et al.. 2015. Complement factor H in its alternative identity as adrenomedullin-binding protein 1.. Mol Immunol 68(1):45-8 PMID: 26597206
- 2. Cheyuo C et al.. 2012. The critical role of adrenomedullin and its binding protein, AMBP-1, in neuroprotection.. Biol Chem 393(6):429-39 PMID: 22628306
- 3. Zudaire E et al.. 2003. Regulation of pancreatic physiology by adrenomedullin and its binding protein.. Regul Pept 112(1-3):121-30 PMID: 12667633
- 4. Wu R et al.. 2006. Preclinical studies with adrenomedullin and its binding protein as cardiovascular protective agents for hemorrhagic shock.. Cardiovasc Drug Rev 24(3-4):204-13 PMID: 17214597
- 5. Fowler DE et al.. 2003. Adrenomedullin and adrenomedullin binding protein-1: their role in the septic response.. J Surg Res 109(2):175-81 PMID: 12643861
- 6. Juaneda C et al.. 2003. Adrenomedullin receptor binding sites in rat brain and peripheral tissues.. Eur J Pharmacol 474(2-3):165-74 PMID: 12921858
- 7. Fowler DE et al.. 2002. The cardiovascular response in sepsis: proposed mechanisms of the beneficial effect of adrenomedullin and its binding protein (review).. Int J Mol Med 9(5):443-9 PMID: 11956648
- 8. Jacob A et al.. 2021. Human adrenomedullin and its binding protein attenuate tissue injury and inflammation following hepatic ischemia reperfusion in rabbits.. Heliyon 7(8):e07845 PMID: 34485732
